Insiders · ENTO

ENTO insider transactions

Entero Therapeutics Inc. (ENTO) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for ENTO

• 254d
  SEC Form 3 filed by new insider Pursglove Geordan Garrett

  3 - Entero Therapeutics, Inc. (0001604191) (Issuer)
• 254d
  SEC Form 3 filed by new insider Sawyer Jason David

  3 - Entero Therapeutics, Inc. (0001604191) (Issuer)
• 440d
  SEC Form 3 filed by new insider Uppal Manpreet

  3 - Entero Therapeutics, Inc. (0001604191) (Issuer)
• 440d
  SEC Form 3 filed by new insider Corbett Eric

  3 - Entero Therapeutics, Inc. (0001604191) (Issuer)
• 440d
  SEC Form 3 filed by new insider Paolone Richard

  3 - Entero Therapeutics, Inc. (0001604191) (Issuer)
• 476d
  Chief Financial Officer Romano Sarah sold $465 worth of shares (727 units at $0.64), decreasing direct ownership by 4% to 17,287 units (SEC Form 4)

  4 - Entero Therapeutics, Inc. (0001604191) (Issuer)
• 566d
  Chief Financial Officer Romano Sarah sold $212 worth of shares (476 units at $0.45), decreasing direct ownership by 3% to 18,014 units (SEC Form 4)

  4 - Entero Therapeutics, Inc. (0001604191) (Issuer)
• 623d
  SEC Form 3 filed by new insider Ramdeen Timothy R.

  3 - Entero Therapeutics, Inc. (0001604191) (Issuer)
• 666d
  Chief Financial Officer Romano Sarah sold $664 worth of shares (621 units at $1.07), decreasing direct ownership by 3% to 18,490 units (SEC Form 4)

  4 - Entero Therapeutics, Inc. (0001604191) (Issuer)
• 666d
  Chairman and CEO Sapirstein James sold $1,379 worth of shares (1,289 units at $1.07), decreasing direct ownership by 3% to 35,816 units (SEC Form 4)

  4 - Entero Therapeutics, Inc. (0001604191) (Issuer)
• 686d
  Director Khosla Chaitan Phd was granted 24,889 shares (SEC Form 4)

  4 - Entero Therapeutics, Inc. (0001604191) (Issuer)